The surgical management and treatment of metastatic lesions in the proximal femur
A mini review
Helin Feng, MD, Jin Wang, MD, Jianfa Xu, MD, Wei Chen, MD, Yingze Zhang, MD*

Abstract
Review current treatments of metastatic lesions in the proximal femur.
We reviewed published literature related to diagnosis and surgical treatments and summarized current treatment options. Surgical management mainly consist of internal fixation, hip replacement, and percutaneous femoroplasty (PFP) which has been newly applied in clinical practice.
An appropriate series of treatments is necessary for patients to avoid the occurrence of paraplegia and prolong survival time.

Abbreviations: CT = computed tomography, ECT = emission computed tomography, MRI = magnetic resonance imaging, PET = positron emission tomography, PFN = proximal femoral nail, PFP = percutaneous femoroplasty, PMMA = polymethylmethacrylate, PVP = percutaneous vertebroplasty, SPECT = single-photon emission tomography.

Keywords: metastases, percutaneous femoroplasty, proximal femur, surgery

1. Introduction
Metastasis accounts for 90% death of cancer patients. In theory, cancer cells can metastasize anywhere in the body but they usually predominate at one site more often than others. Besides lung and liver, bone is the most common site invaded by cancers and actually nearly all types of cancer can metastasize to the bones, particular for breast cancer, prostate cancer, and multiple myeloma.[1] Many factors caused by cancer cells or arisen by the bone marrow microenvironment in response to cancer cells are keys to activation of osteoclastic bone resorption and regulation of osteoblastic activity in bone metastasis.[2–4] Bone metastasize presents a strong correlation with tumor growth in bone which has been referred to the “vicious cycle”, in which tumor cells promote bone metastasis by osteoclasts, and osteoclastic bone destruction causes the activation of growth factors in the microenvironment that further promote tumor progression.[5] In addition to potting a dismal prognosis, bone metastasizes cause significant morbidity including bone pain, fractures, hypercalcemia, spinal cord compression, and other nerve compression syndromes.[6] The spine, proximal femur, and pelvis are the most common sites of bone metastases.[7,8] Among femur metastatic tumors, 50% of the lesions occur in the femoral neck, 30% occur in the subtrochanteric site, and 20% occur in the intertrochanteric site. These lesions lead to severe bone pain and a high incidence of pathological fractures.[9] The goal of proximal femoral metastasis treatment is to relieve pain, restore weight-bearing abilities, and improve the quality of the patient’s remaining life. The treatment of proximal femoral metastases includes nonsurgical and surgical approaches. The nonsurgical approaches include radiation therapy and pharmacologic treatment such as bisphosphonate while the surgical approaches include internal fixation, hip prostheses replacement, and percutaneous femoroplasty (PFP).[10] Because the femur is a major weight-bearing bone with minimal space for surgical errors, the operative procedure must be carefully planned and meticulously executed, with the aim of achieving durable reconstruction. Therefore, all pertinent information must be carefully considered before surgical treatment, such as the location of the metastasis, the extent of bone involvement and the number of metastatic lesions, the perceived effects on other therapies, the type of primary cancer, and the expected life span. PFP represents a promising treatment option for alleviating the pain and weakness associated with metastatic lesions of the femur. PFP resulted in significant pain relief in the affected limbs and significantly improved quality of life. In this review, we have summarized the advances in diagnosis and treatment options for proximal femur metastases.

2. Diagnosis
Proximal femoral metastases can cause severe pain and even pathological fractures, which can negatively affect a patient’s quality of life. The evaluation of patients with proximal femoral metastases should be performed according to a systematic method.[11] One should never assume that proximal femoral metastasis need to be treated in a specific manner without a definite diagnosis, particularly when determining whether the patient has multiple metastases or multiple myeloma. x-Ray is the
most commonly used method for the diagnosis of bone disease. However, computed tomography (CT) is more advantageous in diagnosis of osteoclastic, osteoblastic, and mixed images of metastases, which is frequently used to assess proximal femur stability. Apart from this, CT plays vital roles in operative planning and postoperative assessment, allowing for accurate measurement of the femoral cortices. However, when there is a demand for a precise image of soft tissues and bone structures, magnetic resonance imaging (MRI) is preferred. Besides accurately detecting bone metastases, MRI offers sensitive and specific detection of early proximal femoral metastases and is able to reveal early pathological changes in the marrow. Other examinations such as emission computed tomography (ECT), single-photon emission tomography (SPECT), and positron emission tomography (PET) have their respective advantages. ECT can detect regions of remodeling that are relevant to bone metastases, infection and bone fractures. SPECT provides better sensitivity and specificity for cancer and metastasis diagnoses. PET is also applied to the staging of systemic diseases in tumor patients. Additionally, if multiple myeloma is suspected, serum immune electrophoresis and bone marrow aspiration should be performed to obtain a definite diagnosis.

Rougroux et al. recommended that the standard diagnostic strategy for patients without a definite primary site should include an x-ray of the affected limb, a whole-body bone scan, laboratory studies, and CTs of the chest, abdomen, and pelvis. These procedures identified the primary lesion in 85% of patients. If the patient has no history of tumors or a definite diagnosis is needed, a needle biopsy is a better choice for the diagnosis of bone metastasis.

3. Surgical management

The proximal femur is the most common site of mechanical failure in metastatic patients due to its load-bearing function and continuous axial and torsional stresses. Approximately, 10% of patients with metastatic disease will sustain a pathologic fracture, and 65% of all fractures that occur in the femur require surgery. Although the majority of tumor patients with skeletal metastases are in the advanced stages of cancer, invasive surgical treatment is usually performed in patients with proximal femur metastases. The relevant stereoscopic surgical treatments fall into two general categories: internal fixation and endoprosthetic replacement. Percutaneous vertebroplasty, which is associated with mild trauma and good analgesic effects, is an effective and widely accepted operational option for patients with vertebral tumors through clinical practice. However, the development and evolution of the use of bone cement outside of the spine has rendered the injection of bone cement a potential treatment option for proximal femur metastases. The concept of percutaneous vertebroplasty has been developed to PFP after being applied to the treatment of femoral metastases. PFP provides a less invasive therapeutic option that offers pain relief and biomechanical stability to patients with proximal femoral metastases. All patients benefited from the new technique as previous studies shown.

3.1. Evaluations prior to surgical treatments

In addition to considering the patient’s general systematic conditions, Mirel scoring system, which is the most widely used tool for describing the risk of pathologic fracture, should always be taken into account. These criteria include the location of the lesion, the extent of the lesion, the pain that occurs with walking, and the lytic or blastic nature of the lesion. If the patient has a score of 9, the risk of pathologic fracture is >33%, and the patient requires prophylactic surgery, such as internal fixation or prosthesis replacement. Mirel criteria reveal the risk of pathologic fracture and can facilitate initial decisions regarding surgical planning (Table 1). Van der Linden et al. argued that axial cortical involvement >30 mm is associated with a higher risk of fracture in cases of proximal femoral metastasis. For these impending fractures, the most appropriate strategies are surgical interventions which can provide mechanical stability before a fracture occurs.

3.2. Treatment with prosthetic replacements

Once a fracture occurs in cases of metastatic lesions, nonsurgical treatments always have inevitable limitations; for example, catagmatic bone cannot be sufficiently immobilized, which prevents recovery and results in sustained pain. Because pathologic fractures often exhibit delayed union or even non-union, prosthetic replacements are recommended for patients who have suffered such fractures. Prosthetic replacements not only reconstruct the destroyed lesion but are also used to salvage failed internal fixations or nonsurgical treatments. Standard prostheses are widely used for lesions located in the femoral head and neck. However, if a standard prostheses is inadequate, particularly when there is substantial bone loss in the peritrochanteric region, tumor prosthesis can be applied. Additionally, if the integrity of the acetabulum is sufficient, bipolar hemiarthroplasty is a better option for patients because the complication rate of this procedure is lower than that of a total hip replacement (4% vs. 22.2%). Paul suggested that impending femoral neck lesions should be treated with arthroplasty. In brief, prostheses are an excellent choice for the treatment of proximal femoral metastases in patients with good general fitness and life expectancy. Although the risks of dislocation and infection are high, this method ensures major

---

**Table 1**

| Variable | Score
|----------|-------|
|          | 1     | 2     | 3     |
| Site     | Upper limb | Lower limb | Peritrochanter |
| Pain     | Mild    | Moderate | Activity-related |
| Lesion type | Blastic | Mixed | Lytic |
| Size     | Less than one-third of the cortical diameter | One- to two-thirds of the cortical diameter | More than two-thirds of the cortical diameter |

NOTE: A score of 7 or lower indicates that the patient should be treated with radiation only, and a score of 8 or higher indicates that the patient should undergo prophylactic surgical fixation. Adapted with permission from Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathological fractures. Clinton Orthop Relat Res 1989; (249):256-64.
local tumor control, and the complication and failure rates are not significantly higher than those of osteosynthesis, especially when the latter procedure is associated with curettage and the use of adjuvant cement (Fig. 1).

3.3. Treatment with internal nail fixation

Pathologic intertrochanteric or subtrochanteric fractures may be treated with a cephalomedullary nail or with a prosthetic replacement.[25–27,34,40] The indications for choosing a prosthetic replacement or a cephalomedullary nail are still not clear. Piatek et al.[41] argued that treatment with a gamma nail or a proximal femoral nail may be appropriate for subtrochanteric metastases with a distance to trochanter >20 mm. In general, if the bone in the femoral neck and head is adequate to support the implant, nailing is preferred.[34] Several studies have demonstrated that patients can achieve satisfactory pain relief and marked clinical improvement with improved weight-bearing ability following internal nail fixation operations.[24,42,43] When the surgery is performed, proximal reaming should also be performed as carefully and gently as possible to avoid lateral cortical fracture and embolization. Adequate bone available proximally for fixation is necessary, and distal interlocking is mandatory.[34]

For patients with impending intertrochanteric or subtrochanteric fractures, the bone can be stabilized with cephalomedullary nailing because head and neck fixation may be appropriate for subtrochanteric metastases with a distance to trochanter >20 mm. In general, if the bone in the femoral neck and head is adequate to support the implant, nailing is preferred.[14] Several studies have demonstrated that patients can achieve satisfactory pain relief and marked clinical improvement with improved weight-bearing ability following internal nail fixation operations.[24,42,43] When the surgery is performed, proximal reaming should also be performed as carefully and gently as possible to avoid lateral cortical fracture and embolization. Adequate bone available proximally for fixation is necessary, and distal interlocking is mandatory.[34]

3.4. Treatment with PFP

The first application of polymethylmethacrylate (PMMA) bone cement was conducted by Deramond et al.[47] They injected PMMA into C2 vertebra affected by vertebral hemangiomas and observed remarkable chronic pain relief.[48] Gradually, the use of PMMA following an analogous percutaneous and minimally invasive manipulation method with the assistance of radiology guidance has been found to be favorable for vertebral fractures associated with osteoporosis and painful vertebra with broad osteolysis or invasion secondary to a tumor.[49] An effective and minimally invasive surgical technique is desired for the management of many advanced cancers in patients with severe bone pain who cannot tolerate a major surgery and in patients for whom radiotherapy has already been ineffective and therefore only desire pain relief, minimal trauma, and reduced costs. PMMA may possess many advantages for achieving these goals, including bio-inertness, ease of management, relatively high biomechanical strength, and extended sustainability. The injection of bone cement can strengthen the transmission of bone-to-implant and implant-to-bone forces.[50] Previous studies have demonstrated the efficiency of bone cement injection in proximal femoral metastases.[10,33,51] PFP is a minimally invasive therapy that can provide a facile but effective reinforcement of the proximal femur and reduce the risk of fracture[52,53] (Fig. 2).

Main indications for the PFP treatment of proximal femoral metastases include the following: patients present with steady vital signs, without severe heart or lung disease, or topical inflammation and ulceration; the lesion site should involve primarily osteolytic damage, and the cortex around lesion should be complete, particularly within the calcareofemoral; pathological fractures must not be present. And these components are recommended for: PFP is not recommended for osteoblastic metastases. Given the large volume of bone cement injected in a topical position, the injection should be performed before the bone cement becomes solidification. During the operation, pulse oximetry should be monitored closely to avoid pulmonary embolism. Bone cement leakage represents a common complication of PFP. In the event of leakage, the needle should be repositioned by fluoroscopy to prevent further leakage. In addition, compression of the osteoclasia or soft tissue lump can...
cause cancerous cells to transfer into blood, which could accelerate the process of metastasis.

Regarding weight-bearing capacity and biomechanical stabilization after PFP, the injection of bone cement can sufficiently strengthen and reinforce the destroyed bone. Several studies have shown that cement injections performed in different ways can result in different outcomes. Hayashi et al. claimed that filling the femoral neck with bone cement could improve the mechanical stability of the hip (when loads are applied to the greater trochanter) and protect against fractures of the proximal femur. Palumbo et al. reported that bicortical cement columns spanning from the superior to inferior femoral neck cortices play important roles in restoring the integrity of the femoral neck and improving the load-bearing capacity of the proximal femur. Beckmann et al. showed that single central and centrodorsal bone cement filling patterns significantly improve the mechanical stability of the hip, but double craniocaudal augmentation degenerates the skeleton and results in markedly reduced peak loads and decreased energies to the point of failure. Sutter et al. reported that 15 mL of cement is inadequate to reinforce the proximal femur and there is little biomechanical advantage to placing the cement in the proximal femur when compared with placing it in the trochanter.

Why is PFP so effective? The chemotoxicity and thermal necrosis during exothermic polymerization might account for the possible mechanisms of PMMA in pain relief. PFP may alleviate pain via the damage of the sensitive nerve endings in periosteum. The role of methylmethacrylate (MMA), a component of PMMA, in cell toxicity, neurotoxicity, and chemotoxicity remains unclear and opposite opinions have arisen in previous studies. After ruling out the “chemical effect” and “thermal effect” as probable causes of pain relief, “mechanical stabilization” can be regarded as the second most likely reason for pain relief. In a previous study, PMMA was found to restore the mechanical stability of the bone by stabilizing the micro-motions of micro-trabecular fractures, which are the most frequently observed histologic change in patients. At present, the most likely mechanism of pain relief is the mechanical stabilization. Our previously PFP procedures performed and observed an encouraging curative effect, however, the proposed indications should be strictly followed, as shown Table 2.

4. Overview and conclusion
By the time metastatic tumors are diagnosed, patients have advanced disease; thus, even with the recent advances in the treatment of primary cancers, the survival of patients with bone metastases remains poor. The goals of treatments of proximal femoral metastatic tumors (particularly surgical treatments) are to maximize pain relief, prevent pathologic fractures, provide mechanical stabilization, and enable weight-bearing. For patients with pathologic fractures and ossified metastatic tumors in the proximal section of the femur, prosthetic replacement

| Table 2 | Main indications and recommendations for the PFP treatment of proximal femoral metastases. |
|---|---|
| Indications | Recommendations |
| 1. Patients present with steady vital signs, without severe heart or lung disease, or topical inflammation and ulceration | 1. PFP is not recommended for osteoblastic metastases |
| 2. The lesion site should involve primarily osteolytic damage, and the cortex around lesion should be complete, particularly within the calcar femorale | 2. Given the large volume of bone cement injected in a topical position, the injection should be performed before the bone cement becomes solidification |
| 3. Pathological fractures must not be present | 3. During the operation, pulse oximetry should be monitored closely to avoid pulmonary embolism |
| 4. Bone cement leakage represents a common complication of PFP. In the event of leakage, the needle should be repositioned by fluoroscopy to prevent further leakage | 4. Bone cement leakage represents a common complication of PFP. In the event of leakage, the needle should be repositioned by fluoroscopy to prevent further leakage |

PEP = percutaneous femoroplasty.
following proximal femoral resection is an appropriate operative choice. Internal nail fixation may be suitable for patients with good proximal bone stock. For patients without fractures and with continuous cortical bone metastatic tumors, PFP may be an attractive option when the goal is to simply relieve pain. The importance of careful and appropriate preoperative assessment before the execution of any therapeutic procedure should be emphasized. A carefully considered multidisciplinary approach will provide patients the best opportunity for an improved quality of life and maximal satisfaction. The patient provided written informed consent for the publication of these pictures and the study was approved by the Human Ethics and Research Ethics committees of the Fourth Hospital of Hebei Medical University.

References

[1] Coleman RE. Bone cancer in 2011: prevention and treatment of bone metastases. Nat Rev Clin Oncol 2012;9:76–8.
[2] Johnson RW, Merkel AR, Page JM, et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis 2014;31:945–59.
[3] Zhang X, Akech J, Browne G, et al. Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer 2013;136:1321–32.
[4] Luis-Ravelo D, Antion I, Zandueta C, et al. A gene signature of bone metastatic colonization sensitisizes for tumor-induced osteolysis and predicts survival in lung cancer. Oncogene 2014;33:5090–9.
[5] Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7.
[6] Clines GA, Guise TA. Mechanical mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7.
[7] Laufer I, Sculba DM, Madera M, et al. Surgical management of metastatic spinal tumors. Cancer Control 2012;19:122–8.
[8] Sun G, Jin P, Liu XW, et al. Cementoplasty for managing painful bone metastases outside the spine. Eur Radiol 2014;24:731–7.
[9] Nazario J, Tam AL. Ablation of bone metastases. Surg Oncol Clin N Am 2011;20:355–68, ix.
[10] Feng H, Feng J, Li Z, et al. Percutaneous femoroplasty for the treatment of proximal femoral metastases. Eur J Surg Oncol 2014;40:402–5.
[11] Badia A, Radaulescu R, Sajin M, et al. Immunohistochemistry in diagnosis and surgical treatment of femoral bone metastasis. Rom J Morphol Embryol 2014;55:135–63.
[12] Khandekar S, Dive A, Munde P, et al. Chondroblastic osteosarcoma of the left zygomatic bone: rare case report and review of the literature. J Oral Maxillofac Pathol 2014;18:281–8.
[13] Salapura V, Jeromel M. Minimally invasive (percutaneous) treatment of metastatic spinal and extradural disease—a review. Acta Clin Croat 2014;53:44–54.
[14] Salou G, Kocheid m, Lehmenn P, et al. Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement. Radiology 2010;254:892–90.
[15] Plancarte-Sanchez R, Guzman-Rosas J, Cerezo-Camacho O, et al. Femoroplasty: a new option for femur metastasis. Pain Pract 2013;13:409–13.
[16] Javack PS, Barker J, Baker M, et al. Surgical management of metastatic disease of the proximal part of the femur. J Bone Joint Surg Am 2014;96:2091–8.
[17] Van der Linden YM, Dijkstra PD, Kroon HM, et al. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br 2004;86:666–73.
[18] Gosling T, Becker-Schiele M. [Surgical treatment of skeletal metastases]. Unfallchirurg 2015;118:347–63.
[19] Katzer A, Meenem NM, Grabele F, et al. Surgery of skeletal metastases. Arch Orthop Trauma Surg 2002;122:351–8.
[20] Weidn R, Bauer HC. Surgical treatment of metastatic skeletal lesions of the proximal femur: endoprosthesi s or reconstruction nailing. J Bone Joint Surg Br 2003;85:1653–7.
[21] Zheng K, Peng ZN, Zheng PP. Chondrosarcoma of the proximal humerus secondary to ollier disease: an 8-year follow-up of successful resection of the tumor with endoprosthetic replacement of the proximal humerus. J Clin Med Res 2014;6:218–22.
[22] Steensma M, Healey JH. Trends in the surgical treatment of pathologic proximal femur fractures among Musculoskeletal Tumor Society members. Clin Orthop Relat Res 2013;471:2000–6.
[23] Putle S, Westphal T, Bischoff J, et al. [Intramedullary stabilisation of metastatic fractures of long bones]. Zentralbl Chir 2003;128:131–8.
[24] Assal M, Zanon X, Peter RE. Osteosynthesis of metastatic lesions of the proximal femur with a solid femoral nail and interlocking spiral blade inserted without reaming. J Orthop Trauma 2000;14:394–7.
[25] Moholkar K, Mohan R, Gregoris P. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg 2004;70:429–34.
[26] Djistra S, Wiggers T, van Geel BN, et al. Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures. Eur J Surg 1994;160:535–42.
[27] Samsani SR, Panikkar V, Venu KM, et al. Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol 2004;30:991–7.
[28] van Doorn R, Stapert JW. Treatment of impending and actual pathological femoral lesions with the Long Gamma Nail. Eur J Radiol 2005;53:44–54.
[29] Deramond H, Depriester C, Toussaint P, et al. Percutaneous vertebroplasty. Semin Musculoskelet Radiol 1997;1:285–96.
[48] Galibert P, Deramond H, Rosat P, et al. [Preliminary note on the treatment of vertebral angiomia by percutaneous acrylic vertebroplasty]. Neurochirurgie 1987;33:166–8.
[49] Yimin Y, Zhiwei R, Wei M, et al. Current status of percutaneous vertebroplasty and percutaneous kyphoplasty—a review. Med Sci Monit 2013;19:826–36.
[50] Arora M, Chan EK, Gupta S, et al. Polymethylmethacrylate bone cements and additives: A review of the literature. World J Orthop 2013;4:67–74.
[51] Plancarte R, Guajardo J, Meneses-Garcia A, et al. Clinical benefits of femoroplasty: a nonsurgical alternative for the management of femoral metastases. Pain Physician 2014;17:227–34.
[52] Beckmann J, Ferguson SJ, Gebauer M, et al. Femoroplasty—augmentation of the proximal femur with a composite bone cement—feasibility, biomechanical properties and osteosynthesis potential. Med Eng Phys 2007;29:755–64.
[53] Sutter EG, Wall SJ, Mears SC, et al. The effect of cement placement on augmentation of the osteoporotic proximal femur. Geriatr Orthop Surg Rehabil 2010;1:22–6.
[54] Hayashi K, Aono M, Shintani K, et al. Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review. Anticancer Res 2014;34:1245–9.
[55] Palumbo BT, Nalley C, Gaskins RB3rd, et al. Biomechanical analysis of impending femoral neck fractures: the role of percutaneous cement augmentation for osteolytic lesions. Clin Biomech (Bristol, Avon) 2014;29:289–95.
[56] Beckmann J, Springorum R, Vettorazzi E, et al. Fracture prevention by femoroplasty—cement augmentation of the proximal femur. J Orthop Res 2011;29:1733–8.
[57] Anselmetti GC, Manca A, Kanaka K, et al. Temperature measurement during polymerization of bone cement in percutaneous vertebroplasty: an in vivo study in humans. Cardiovasc Intervent Radiol 2009;32:491–8.
[58] Urrutia J, Bono CM, Mery P, et al. Early histologic changes following polymethylmethacrylate injection (vertebroplasty) in rabbit lumbar vertebrae. Spine (Phila Pa 1976) 2008;33:877–82.
[59] Smith HS, Barkin RL. Painful boney metasteses. Am J Ther 2014;21:106–30.
[60] Nakano M, Hirano N, Ishihara H, et al. Calcium phosphate cement-based vertebroplasty compared with conservative treatment for osteoporotic compression fractures: a matched case-control study. J Neurosurg Spine 2006;4:110–7.
[61] Antonacci MD, Mody DR, Rutz K, et al. A histologic study of fractured human vertebral bodies. J Spinal Disord Tech 2002;15:118–26.
[62] Selek H, Basarir K, Yildiz Y, et al. Cemented endoprosthetic replacement for metastatic bone disease in the proximal femur. J Arthroplasty 2008;23:112–7.
[63] Utzschneider S, Wicherek E, Weber P, et al. Surgical treatment of bone metastases in patients with lung cancer. Int Orthop 2011;35:731–6.